Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of glufosfamide versus 5-fluorouracil in metastatic pancreatic cancer after gemcitabine progression
CTR20222416Phase 3Active
- Sponsor
- Zhaoke Pharmaceutical
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of glufosfamide, fluorouracil in pancreatic adenocarcinoma (PDAC), sponsored by Zhaoke Pharmaceutical. Started Sep 2022; status: active.
02
Drugs
glufosfamidefluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20222416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222416.